STOCK TITAN

Longevity Health (XAGE) trades lawsuit overhang for 10% secured notes

(Very High)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Longevity Health Holdings, Inc. announced it has entered into a Settlement Agreement with Puritan Partners LLC, resolving litigation that has been pending since November 2023 and described as having constrained access to capital and strategic opportunities. The dispute related to a January 2022 securities purchase agreement, secured convertible note, and warrant issued by subsidiary Carmell Regen Med Corporation. Under the settlement, Longevity exchanged the existing note and warrant for new 10% senior secured convertible notes with an aggregate principal amount of $2,350,000, maturing in February 2028. The parties plan to file a stipulation dismissing the action without prejudice within three business days after execution. Longevity states that resolving the matter removes a significant litigation overhang and allows greater focus on commercial strategy, capital raising, and other strategic opportunities, while cautioning that the new financing instruments involve obligations including potential dilution, security interests in substantially all Company assets and specified subsidiary assets, and repayment and default-related risks.

Positive

  • Settlement removes a significant litigation overhang that had constrained capital raising and strategic opportunities since 2023.
  • Exchange into new notes provides a defined capital structure with $2,350,000 in 10% senior secured convertible notes maturing in February 2028.

Negative

  • New 10% senior secured convertible notes of $2,350,000 carry risks including potential dilution and security interests in substantially all Company and certain subsidiary assets.
  • Company highlights risks related to repayment, prepayment obligations, and default-related remedies under the new financing instruments.

Insights

Analyzing...

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
New notes principal $2,350,000 Aggregate principal amount of new senior secured convertible notes under the Settlement Agreement
Coupon rate 10% Interest rate on the new senior secured convertible notes
Maturity of new notes February 2028 Maturity date of the new senior secured convertible notes
Litigation start November 2023 Date litigation with Puritan Partners LLC commenced
Prior agreement date January 2022 Date of securities purchase agreement, note, and warrant at issue in the litigation
Announcement date August 17, 2026 Date Longevity announced the Settlement Agreement with Puritan Partners LLC
senior secured convertible notes financial
"exchanged the existing note and warrant for new 10% senior secured convertible notes"
A senior secured convertible note is a loan a company issues that sits near the top of its repayment order (senior), is backed by specific assets as collateral (secured), and can be swapped into company shares later (convertible). For investors this matters because it combines lower risk of repayment and legal protection from the collateral with the upside of converting into equity—so it affects both the safety of debt holders and potential dilution for shareholders.
stipulation dismissing the action without prejudice regulatory
"The parties will file a stipulation dismissing the action without prejudice"
security interests financial
"including potential dilution, security interests in substantially all Company assets"
A security interest is a legal claim a lender or creditor has on a borrower's specific assets to ensure repayment; if the borrower fails to pay, the creditor can seize those assets to recoup losses. For investors, security interests change how risky a company's debt and assets are because they determine who gets paid first in financial trouble—think of it like a mortgage on a house that gives one lender first dibs on the sale proceeds.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What litigation did XAGE settle with Puritan Partners LLC?

Longevity Health Holdings (XAGE) entered into a Settlement Agreement with Puritan Partners LLC to resolve litigation arising from a January 2022 securities purchase agreement, secured convertible note, and warrant issued by subsidiary Carmell Regen Med Corporation. The case had been pending since November 2023.

What are the key terms of the new notes issued by XAGE in the settlement?

Under the settlement, Longevity issued 10% senior secured convertible notes with an aggregate principal amount of $2,350,000, maturing in February 2028. These notes replace the prior note and warrant and are secured by substantially all Company assets and specified subsidiary assets.

How does the Puritan settlement affect XAGE’s ability to raise capital?

Management states that the litigation had hindered capital raising and strategic opportunities since November 2023. They describe the settlement as removing a significant litigation overhang, allowing more focus on executing commercial strategy and pursuing additional financing and strategic opportunities.

When will the litigation between XAGE and Puritan Partners be dismissed?

Longevity and Puritan plan to file a stipulation dismissing the action without prejudice within three business days following execution of the Settlement Agreement, formally ending the court case while leaving the settlement terms in place.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001842939 0001842939 2026-08-17 2026-08-17


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

FORM 8-K

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 17, 2026

Longevity Health Holdings, Inc.
(Exact name of Registrant as Specified in Its Charter)

 
Delaware
(State or Other Jurisdiction 
of Incorporation)
001-40228
(Commission File 
Number)
86-1645738
(IRS Employer 
Identification No.)
 
 
 
2403 Sidney Street, Suite 300
 
 
PittsburghPennsylvania
 
15203
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrants Telephone Number, Including Area Code: (412894-8248
(Former Name or Former Address, if Changed Since Last Report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act: None.
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
 

 
Item 8.01 Other Events.
 
On August 17, 2026, the Company issued a press release announcing the settlement of litigation with Puritan Partners LLC.  A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
 
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit
Description
99.1
Press Release, dated August 17, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  
LONGEVITY HEALTH HOLDINGS, INC.
 
By: /s/ Bryan J. Cassaday                 
Name: Bryan J. Cassaday
Title: Chief Financial Officer
Date: August 17, 2026

EXHIBIT 99.1

 

Longevity Health Holdings Announces Settlement of Litigation with Puritan Partners


Settlement resolves litigation pending since 2023 that had constrained the Company’s access to capital and strategic opportunities

 

 

PITTSBURGH, August 17, 2026 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (OTCQB: XAGE) (“Longevity” or the “Company”), a bio-aesthetics company focused on human longevity and healthy aging, announced today that it has entered into a settlement agreement (the “Settlement Agreement”) with Puritan Partners LLC (“Puritan”) to resolve the litigation between the parties.

 

“This litigation has been ongoing since November 2023 and has hindered our ability to raise capital and pursue strategic opportunities during that time,” said Ram Ajjarapu, Chairman and Chief Executive Officer of Longevity. “Resolving this dispute removes a significant litigation overhang and allows us to focus on executing our commercial strategy, raising capital, and pursuing other strategic opportunities. We appreciate having reached terms with Puritan that let us move forward.”

 

Puritan commenced the litigation in November 2023, asserting claims arising out of a January 2022 securities purchase agreement, secured convertible note, and warrant issued by the Company’s subsidiary, Carmell Regen Med Corporation (f/k/a Carmell Therapeutics Corporation). 

 

Under the terms of the Settlement Agreement, Longevity exchanged the existing note and warrant for new 10% senior secured convertible notes in the aggregate principal amount of $2,350,000 maturing in February 2028. The parties will file a stipulation dismissing the action without prejudice within three business days following execution of the Settlement Agreement. A more complete description of the Settlement Agreement and the related transactions is contained in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 14, 2026.

 

About Longevity Health Holdings, Inc.

Longevity Health Holdings, Inc. is focused on longevity and healthy aging, encompassing the latest scientific advances in regenerative bio-aesthetics. The Company develops, manufactures, and markets cosmetic skincare and haircare products designed to help people look and feel their best at any age. The Company is headquartered in Pittsburgh, Pennsylvania. For more information, visit www.healthxage.com. 

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated benefits of the Settlement Agreement, the Company’s plans to pursue additional financing, and the Company’s future business and financial condition. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that anticipated additional financing is not completed on the terms described or at all, risks relating to the Company’s obligations under the Settlement Agreement and the related financing instruments, including potential dilution, security interests in substantially all Company assets and specified subsidiary assets, repayment and prepayment obligations, and default-related remedies, and other risks described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law. 

 

Investor Contact

Bryan Cassaday

bcassaday@healthxage.com

Filing Exhibits & Attachments

5 documents